We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
151
CALL
PTC Therapeutics
PTCT
$6.25B
$1.83M 0.08%
+300
New +$18.3K
FOLD
152
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.8M 0.07%
1,651
+54
+3% +$476
CEMP
153
PUT
DELISTED
Cempra, Inc.
CEMP
$1.77M 0.07%
517
-1,565
-75% -$47.1K
CSLT
154
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.69M 0.07%
+217,600
New +$1.86M
OCRX
155
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.67M 0.07%
354,574
-75,371
-18% -$434K
RPRX
156
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$1.67M 0.07%
1,941
-1,220
-39% -$10.9K
BLRX
157
BioLineRX
BLRX
$12.2M
$1.57M 0.07%
1,241
-307
-20% -$378K
RDHL
158
Redhill Biopharma
RDHL
$4.44M
$1.57M 0.07%
+108
New +$1.54M
RPRX
159
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$1.51M 0.06%
1,753
+5
+0.3% +$45
ARDX icon
160
Ardelyx
ARDX
$1.25B
$1.47M 0.06%
+112,174
New +$2.1M
CYH icon
161
Community Health Systems
CYH
$393M
$1.44M 0.06%
33,358
-18,705
-36% -$775K
ARIA
162
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.43M 0.06%
173,752
+109,864
+172% +$812K
ZSAN
163
DELISTED
Zosano Pharma Corporation
ZSAN
$1.43M 0.06%
+202
New +$1.52M
A icon
164
CALL
Agilent Technologies
A
$39.7B
$1.37M 0.06%
329
-3,008
-90% -$122K
ALDR
165
DELISTED
Alder Biopharmaceuticals
ALDR
$1.35M 0.06%
+46,800
New +$1.28M
CEMP
166
CALL
DELISTED
Cempra, Inc.
CEMP
$1.32M 0.06%
385
-2,151
-85% -$64.7K
ARIA
167
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.32M 0.05%
1,599
-712
-31% -$5.26K
SRPT icon
168
PUT
Sarepta Therapeutics
SRPT
$1.63B
$1.3M 0.05%
+979
New +$13K
ACHC icon
169
CALL
Acadia Healthcare
ACHC
$3.01B
$1.3M 0.05%
+398
New +$25.5K
NBSE
170
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.29M 0.05%
+13
New +$42.9K
BNBX
171
DELISTED
BNB PLUS CORP
BNBX
$1.28M 0.05%
+1
New +$2.01M
VIRX
172
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.25M 0.05%
+24
New +$12.1K
SCPX
173
DELISTED
Scorpius Holdings, Inc.
SCPX
$1.24M 0.05%
+1
New +$1.65M
KYNB
174
Kyntra Bio
KYNB
$28.2M
$1.21M 0.05%
+1,536
New +$1.19M
GNCA
175
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.19M 0.05%
+12,500
New +$882K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.